Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.
Actively Recruiting
Phase 2 Study of mRNA-1195 Shots to Prevent Multiple Sclerosis Relapses in Adults 18 to 55 Years Old
Researchers are evaluating the safety and immune response of mRNA-1195, a potential treatment for adults aged 18 to 55 with multiple sclerosis. The study focuses on participants who have relapsing multiple sclerosis or early signs of the disease and aims to understand how the treatment works compared to a placebo. This Phase 2 trial is sponsored by ModernaTX, Inc. and follows a randomized, observer-blind design to ensure reliable results. Participants are divided into three groups receiving either a low dose or high dose of mRNA-1195, or a placebo. Each participant receives three intramuscular injections scheduled at the start, two months, and six months. The study monitors participants for up to nearly four years, including follow-up for safety and disease progression. During the study, participants undergo regular assessments including MRI scans to monitor brain lesions, blood tests to measure immune response, and evaluations of disability progression. Researchers track side effects, adverse events, and overall health throughout the study period. The primary outcomes focus on safety reactions shortly after injections, while secondary outcomes assess changes in disease activity and immune response over time.
Actively Recruiting
This research aims to evaluate the long-term safety of rimegepant in treating acute migraine attacks in children and adolescents aged 6 to under 18 years. The study focuses on monitoring how well participants tolerate the medication over time and tracking any side effects or safety concerns during treatment. Participants will receive oral doses of rimegepant at 75 mg, 50 mg, or 35 mg as orally disintegrating tablets ODT for acute migraine treatment. This open-label, single-group study follows participants for approximately 58 weeks to assess safety and tolerability, including monitoring liver-related adverse events. Throughout the study, participants will undergo regular assessments including blood sampling and clinical evaluations to monitor adverse events and overall health. Researchers will record the frequency and severity of side effects, serious adverse events, and any lab abnormalities. The total participation duration extends up to 58 weeks, with ongoing safety monitoring during this period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of BHV-3000 rimegepant compared to a placebo for treating moderate or severe migraine attacks in children and adolescents aged 6 to under 18 years. This Phase 3 study focuses on acute treatment for pediatric migraine, including cases with or without aura, aiming to better understand how well rimegepant relieves migraine pain and associated symptoms shortly after dosing. Participants are randomly assigned to receive either BHV-3000 at doses of 75 mg or 50 mg orally disintegrating tablet ODT or a matching placebo tablet. The study uses a triple-blind design to compare outcomes between these groups. The trial includes children and adolescents who experience 1 to 8 moderate or severe migraine attacks monthly, with attacks lasting over 3 hours. Some participants may continue stable preventive migraine medications except CGRP antagonists. The study monitors patients during the acute migraine attack treatment phase. During the study, participants will be assessed for pain freedom two hours after dosing as the primary outcome, as well as secondary outcomes such as freedom from the most bothersome migraine symptoms, need for rescue medication within 24 to 48 hours, sustained pain freedom, and ability to function normally. Safety and efficacy data will be collected throughout. The total duration of participation varies depending on individual treatment and follow-up requirements, with the primary completion planned by January 2029.
Actively Recruiting
Migraine is a common neurological disorder causing moderate to severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. This research aims to evaluate the safety and effectiveness of ubrogepant, a medication approved for adults, in treating acute migraine attacks in children and adolescents aged 6 to 17 years. The study includes two groups a pharmacokinetic PK cohort for younger children and a main randomized study involving both children and adolescents. Participants aged 6 to 11 in the PK cohort will receive two different doses of ubrogepant to determine the appropriate dose for the main study. In the main study, after dose selection, children aged 6 to 11 and adolescents aged 12 to 17 will be randomly assigned to receive either a low dose, high dose of ubrogepant, or placebo, with a 1 in 3 chance of placebo assignment. For qualifying migraine attacks, participants will take oral tablets of the assigned study intervention and may take a second dose or rescue medication at least 2 hours later if the headache persists. Participants will attend regular visits at a hospital or clinic for up to 6 months. Researchers will monitor the effects of treatment through medical assessments, blood tests, side effect checks, and questionnaires. The main outcome measured is the percentage of participants who are free from pain 2 hours after the initial dose. Safety and tolerability will also be assessed throughout the study duration.